A Study To Examine The Safety, Tolerability And Pharmacokinetics Of PF-02545920 In Psychiatrically Stable Subjects With Schizophrenia

• Drug: PF-02545920
  
  15 mg (2 mg X 2d, 5 mg X 2d, 8 mg X 3 d, then 15 mg) Q12h
  Other Name: Cohort 1
• Drug: PF-02545920
  
  15 mg (5 mg X 2d, 10 mg X 2d, then 15 mg) Q12h
  Other Name: Cohort 2
• Drug: PF-02545920
  
  15 mg (5 mg BID for 7 days 10 mg BID for 7 days, then 15 mg BID for 4 days) Q12h
  Other Name: Cohort 3
• Drug: Placebo
  
  Placebo Q12h

• Experimental: PF-02545920
  
  Interventions:
  

  • Drug: PF-02545920
  • Drug: PF-02545920
  • Drug: PF-02545920
• Placebo Comparator: Placebo
  
  Intervention: Drug: Placebo

Inclusion Criteria:

• Psychiatrically stable subjects with schizophrenia.
• Evidence of stable schizophrenia symptomatology greater than or equal to 3 months.
• Subjects must be on a stable medication treatment regimen greater than or equal to 2 months, including concomitant psychotropic medications.

Exclusion Criteria:

• History of seizures or of a condition with risk of seizures.
• Subjects who have had electroconvulsive therapy within the 6 months prior to randomization.
• Pregnant or nursing females, and females of child bearing potential.